Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245883 | 0.76 | PHF8 (0.55) | KDM6BKDM5CEGLN1PHF8KDM2A | |
| SCHEMBL247611 | 0.74 | MAPK1 (0.42) | CYP2D6HDAC1HDAC2HDAC6 | |
| SCHEMBL15470670 | 0.71 | EGLN1 (0.42) | KDM6BKDM5CEGLN1PHF8KDM2A | |
| SCHEMBL31476759 | 0.70 | HDAC6 (0.35) | HDAC1HDAC2HDAC6 | |
| SCHEMBL17506142 | 0.70 | EGLN1 (0.41) | KDM6BKDM5CEGLN1PHF8KDM2A | |
| SCHEMBL11679497 | 0.70 | EGLN1 (0.41) | KDM6BKDM5CEGLN1PHF8KDM2A | |
| SCHEMBL30396313 | 0.70 | MEN1 (0.42) | CYP2D6 | |
| SCHEMBL18206866 | 0.69 | EGLN1 (0.37) | KDM6BKDM5CEGLN1PHF8KDM2A | |
| SCHEMBL18206869 | 0.69 | EGLN1 (0.37) | KDM6BKDM5CEGLN1PHF8KDM2A | |
| SCHEMBL14294646 | 0.69 | KDM6B (0.34) | KDM6BKDM5CEGLN1PHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512158-B2 | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes | NEWLINK GENETICS CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| EP-2089051-B1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NEWLINK GENETICS (US) | 2016-11-30 | — | — | EP | disclosed |
| US-8916169-B2 | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes | NEWLINK GENETICS CORPORATION (US) | 2014-12-23 | — | — | US | disclosed |
| US-8357777-B2 | Enhanced immunogenicity of tumor associated antigens by addition of αgal epitopes | NEWLINK GENETICS (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120003251-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NEWLINK GENETICS (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2089051-A2 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | Newlink Genetics (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008057235-A9 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NEWLINK GENETICS (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008057235-A2 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NEWLINK GENETICS (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003251-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | ENGASE, GALE, FUT5 | KDM6B 2548/4885KDM5C 2053/4885EGLN1 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.